Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;28(6):e14836.
doi: 10.1111/petr.14836.

Detection of Subclinical Rejection in Pediatric Kidney Transplantation: Current and Future Practices

Robert B Ettenger  1 , Michael E Seifert  2 , Tom Blydt-Hansen  3 , David M Briscoe  4 , John Holman  5 , Patricia L Weng  1 , Rachana Srivastava  1 , James Fleming  5 , Mohammed Malekzadeh  1 , Meghan Pearl  1
Affiliations
Review

Detection of Subclinical Rejection in Pediatric Kidney Transplantation: Current and Future Practices

Robert B Ettenger et al. Pediatr Transplant. 2024 Sep.

Abstract

Introduction: The successes in the field of pediatric kidney transplantation over the past 60 years have been extraordinary. Year over year, there have been significant improvements in short-term graft survival. However, improvements in longer-term outcomes have been much less apparent. One important contributor has been the phenomenon of low-level rejection in the absence of clinical manifestations-so-called subclinical rejection (SCR).

Methods: Traditionally, rejection has been diagnosed by changes in clinical parameters, including but not limited to serum creatinine and proteinuria. This review examines the shortcomings of this approach, the effects of SCR on kidney allograft outcome, the benefits and drawbacks of surveillance biopsies to identify SCR, and new urine and blood biomarkers that define the presence or absence of SCR.

Results: Serum creatinine is an unreliable index of SCR. Surveillance biopsies are the method most utilized to detect SCR. However, these have significant drawbacks. New biomarkers show promise. These biomarkers include blood gene expression profiles and donor derived-cell free DNA; urine gene expression profiles; urinary cytokines, chemokines, and metabolomics; and other promising blood and urine tests.

Conclusion: Specific emphasis is placed on studies carried out in pediatric kidney transplant recipients.

Trial registration: ClinicalTrials.gov: NCT03719339.

Keywords: biomarkers; pediatric kidney transplantation; subclinical rejection.

PubMed Disclaimer

References

    1. R. Saran, B. Robinson, K. C. Abbott, et al., “US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States,” American Journal of Kidney Diseases 73, no. 3 Suppl 1 (2019): A7–A8.
    1. R. Ettenger, H. Chin, K. Kesler, et al., “Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation,” American Journal of Transplantation 17, no. 6 (2017): 1549–1562.
    1. M. H. Pearl and E. F. Reed, “Angiotensin II Type I Receptor Antibodies in Pediatric Solid Organ Transplant,” Human Immunology 80, no. 8 (2019): 568–572.
    1. P. A. Clayton, S. P. McDonald, G. R. Russ, and S. J. Chadban, “Long‐Term Outcomes After Acute Rejection in Kidney Transplant Recipients: An ANZDATA Analysis,” Journal of the American Society of Nephrology: JASN 30, no. 9 (2019): 1697–1707.
    1. R. Ettenger, R. Albrecht, R. Alloway, et al., “Meeting Report: FDA Public Meeting on Patient‐Focused Drug Development and Medication Adherence in Solid Organ Transplant Patients,” American Journal of Transplantation 18, no. 3 (2018): 564–573.

Associated data

LinkOut - more resources